By SPC staff
The FDA approved insulin glargine-aglr (Eli Lilly, Rezvoglar) as the second interchangeable biosimilar insulin product to Lantus (Sanofi).
Insulin glargine-aglr is a long-acting human insulin analog for adults and children with diabetes mellitus, available in 3-mL prefilled pens and administered once daily. It previously secured approval as a biosimilar to insulin glargine last December. The first biosimilar to be approved as interchangeable with the reference product was insulin